CRVO CERVOMED INC

CervoMed to Participate in Upcoming Investor Conferences

CervoMed to Participate in Upcoming Investor Conferences

BOSTON, March 05, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced that Company management will participate in the following investor conferences during the month of March:

Leerink Global Healthcare Conference

Format: 1x1 Investor Meetings

Date: Wednesday, March 11, 2026

38th Annual ROTH Conference

Format: Fireside Chat & 1x1 Investor Meetings

Presentation Date: Monday, March 23, 2026

Presentation Time: 12:00 – 12:30 PM PT

The webcast of the fireside chat will be accessible in the Investor section of the CervoMed website

About CervoMed

CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an oral small molecule targeting critical disease processes underlying degenerative disorders of the brain by inhibiting a key enzyme involved in neuroinflammation and neurodegeneration. CervoMed’s recently completed Phase 2b RewinD-LB trial evaluated neflamapimod in DLB patients who have a low likelihood of AD co-pathology, and the Company plans to initiate a global, pivotal Phase 3 trial in the same patient population in the second half of 2026, subject to available funding.

Contacts:

Media:

Lisa Guiterman

Biongage Communications



202-330-3431

Investor Relations:

Argot Partners



212-600-1902 



EN
05/03/2026

Underlying

CRVOCERVOMED INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CERVOMED INC

 PRESS RELEASE
Free
CRVO CERVOMED INC

CervoMed to Participate in Upcoming Investor Conferences

CervoMed to Participate in Upcoming Investor Conferences BOSTON, March 05, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced that Company management will participate in the following investor conferences during the month of March: Leerink Global Healthcare Conference Format: 1x1 Investor MeetingsDate: Wednesday, March 11, 2026 38th Annual ROTH ConferenceFormat: Fireside Chat & 1x1 Investor MeetingsPresentation Date: Monday, March 23, 2026Presentation Time: 12:00 – 12:30 PM ...

March 5, 2026 1 EN
 PRESS RELEASE
Free
CRVO CERVOMED INC

CervoMed Announces Selection of Formulation and Dosing Regimen for Pla...

CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies Bioavailability data recently obtained from Phase 1 study with a stable crystal form of neflamapimod manufactured using a new, controlled manufacturing process Pharmacokinetic profile of the new, stable crystal form of neflamapimod largely overlaps with the therapeutically active drug product used in Phase 2b trial extension To ensure that plasma drug concentrations associated with therapeutic activity are achieved, dosing regimen in the planned Phase 3 trial...

March 4, 2026 1 EN
 PRESS RELEASE
Free
CRVO CERVOMED INC

CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platfo...

CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform designed to prioritize promising treatments for Amyotrophic Lateral Sclerosis Neflamapimod endorsement based on targeted mechanism of action, demonstrated clinical activity in neurodegenerative diseases, and encouraging translational data in ALS-relevant neurotoxicity models UK-based trial first to evaluate neflamapimod in ALS; first person with ALS expected to be dosed by end of 2026 Trial costs funded by United Kingdom government and leading motor neuron disease charities BOSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -...

February 18, 2026 1 EN
 PRESS RELEASE
Free
CRVO CERVOMED INC

CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demo...

CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies Phase 2b trial showed significant improvements on primary and key secondary outcomes measures, most prominently in patients without AD co-pathology Significant reduction in key neurodegeneration biomarker correlated with treatment response, suggesting neflamapimod may act on underlying disease CervoMed preparing to initiate Phase 3 registrational trial in patients with DLB in the second half of 2026 BOSTON, Dec. 04, 2025 (GL...

December 4, 2025 1 EN
 PRESS RELEASE
Free
CRVO CERVOMED INC

CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimo...

CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB) 1st of two presentations with results from Phase 2b study of neflamapimod at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference Data demonstrates neflamapimod treatment led to significant reductions in plasma glial fibrillary acidic protein (GFAP), a key marker of neuroinflammation-associated neurodegeneration, and increased beta amyloid (A) 42/40 ratio in DLB Correlation of the effects of neflamapimod on plasma ...

December 2, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch